Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.14
-0.03 (-0.16%)
Sep 3, 2025, 3:34 PM - Market open
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.11T JPY in the quarter ending June 30, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to 4.48T, up 1.52% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,480.25B JPY
Revenue Growth
+1.52%
P/S Ratio
1.53
Revenue / Employee
94,410,410 JPY
Employees
47,455
Market Cap
47.48B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TAK News
- 12 days ago - What's Going On With Takeda Stock On Friday? - Benzinga
- 13 days ago - Japan's Takeda weighs India for global trials to speed up drug launches - Reuters
- 26 days ago - Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis - Newsfile Corp
- 4 weeks ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 5 weeks ago - Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression - Business Wire
- 6 weeks ago - Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration - Business Wire
- 6 weeks ago - Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector - Seeking Alpha